Depression, Major Depressive Disorder
Conditions
Keywords
MDD, Child, Adolescent, Pharmacokinetic, Outpatient, Pediatrics, Depressive Disorder, Major
Brief summary
The primary purpose of this study is to test the safety and tolerability of single ascending doses of Desvenlafaxine Succinate Sustained-Release (DVS SR) in both child and adolescent outpatients with major depressive disorder. This study will also characterize the pharmacokinetic profile of DVS SR in children and adolescents with major depressive disorder.
Interventions
DVS SR Tablets of 10mg, 25mg, 50mg, and 100mg. Assigned DVS SR daily doses of 10mg, 25mg, 50mg, 100mg, or 200mg for up to 8 weeks.
Sponsors
Wyeth is now a wholly owned subsidiary of Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
7 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* Male or female outpatient between 7 and 17 years of age at baseline who meet Diagnostic and Statistic Manual of Mental Disorders, Fourth Edition, Text Revision criteria for major depressive disorder. * Children's Depression Rating Scale --Revised (CDRS-R) score greater than 40 at the screening and study day -1 (baseline) visits and Clinical Global Impressions Scale--Severity (CGI-S) score of greater than or equal to 4 at the screening and study day -1 (baseline) visits. * Depression of at least moderate severity with symptoms for at least 1 month before screening and that could, in the investigator's opinion, respond to therapy with antidepressant(s) alone (without concomitant psychotherapy). * Other inclusion criteria apply.
Exclusion criteria
* History or current evidence of a medical condition known to interfere with the absorption or excretion of drugs or a history of surgery known to interfere with the absorption or excretion of drugs; history or presence of any other medical condition that might confound the study or put the study participant at greater risk during participation; known hypersensitivity to venlafaxine. * History of suicide attempt or gesture in which the intent was suicide or serious self-harm or acute suicidality to such a degree that precaution against suicide must be exercised. * Current (within 12 months before baseline) psychoactive substance abuse or dependence (including alcohol), manic episode, posttraumatic stress disorder, obsessive-compulsive disorder, or a diagnosis of bipolar disorder or psychotic disorder or current (within 12 months before baseline) generalized anxiety disorder, panic disorder, social anxiety disorder, or attention deficit hyperactivity disorder (ADHD) if considered by the investigator to be primary (causing a higher degree of distress or impairment than MDD) or presence (within 12 months before baseline) of a clinically important personality disorder (such as antisocial, schizotypal, histrionic, borderline, or narcissistic) as assessed during the psychiatric evaluations or history or presence of MDD with psychotic features. * Other
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | Pre-dose (0 hour) and Post-dose (0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours) on Days 28 and 56 | Noncompartmental pharmacokinetic (PK) parameter obtained using 0 to 72 hour concentration data from venous blood samples measured as nanograms per milliliter (ng/mL). |
| Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Baseline to Follow-up (up to Day 77) | AEs are any untoward, undesired, or unplanned event in the form of signs, symptoms, disease, or laboratory or physiologic observations occurring in a person given study treatment. The event does not need to be causally related to the study treatment. SAEs are adverse events that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in persistent or significant disability or incapacity, result in cancer, or result in a congenital anomaly or birth defect. |
| Plasma Decay Half-Life (t1/2) | Pre-dose (0 hour) and Post-dose (0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours) on Days 28 and 56 | Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Noncompartmental PK parameter obtained using 0 to 72 hour concentration data from venous blood samples measured as hours (hr). |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | Pre-dose (0 hour) and Post-dose (0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours) on Days 28 and 56 | Noncompartmental PK parameter obtained using 0 to 72 hour concentration data from venous blood samples measured as hours (hr). |
| Area Under the Curve From Time Zero to Infinity (AUC0-∞) | Pre-dose (0 hour) and Post-dose (0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours) on Days 28 and 56 | AUC (0-∞) = Area under the plasma concentration versus time curve from time zero (pre-dose) to infinity. Noncompartmental PK parameter obtained using 0 to 72 hour concentration data from venous blood samples measured as nanograms multiplied by hours divided by milliliters (ng\*hr/mL). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Population Pharmacokinetics Dose Normalized AUC (AUC/D): Third Method | Day 1, Day 28, and Day 56 | Relationship of variables (i.e., age, sex, ethnicity, and food) examined by fitting dose normalized AUC (AUC/D) values to a power model. AUC/D regressed against variables using power equation Y=A\*W\^b (Y=AUC/D; A=coefficient; W=variable; b=exponent). AUC values from children cohort (ages 7 to 11) combined doses=first method of analysis. AUC from adolescent cohort (ages 12 to 17) combined doses=second method of analysis. AUC values combined from both cohorts=third method of analysis. Measured as nanograms multiplied by hours divided by milliliters per milligram of dose \[(ng\*hr/mL)/mg of dose\]. |
| Population Pharmacokinetics Dose Normalized AUC (AUC/D): First Method, Second Method | Day 1, Day 28, and Day 56 | Relationship of variables (i.e., age, sex, ethnicity, and food) examined by fitting dose normalized AUC (AUC/D) values to a power model. AUC/D regressed against variables using power equation Y=A\*W\^b (Y=AUC/D; A=coefficient; W=variable; b=exponent). AUC values from children cohort (ages 7 to 11) combined doses=first method of analysis. AUC from adolescent cohort (ages 12 to 17) combined doses=second method of analysis. AUC values combined from both cohorts=third method of analysis. Measured as nanograms multiplied by hours divided by milliliters per milligram of dose \[(ng\*hr/mL)/mg of dose\]. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Baseline, Inpatient Days 1 to 4, Outpatient Days 5 to 7, Outpatient Weeks 2 through 8 and Outpatient Week >8 (or early termination) | CDRS-R total score: scale measures 17 depressive symptoms, of which 3 are rated 1 to 5 and 14 are rated 1 to 7 (1 = no symptom difficulties; 5 or 7 = severe clinically significant difficulties) for a total score range of 17 to 113. Lower total scores indicate lower intensity of symptoms. |
| Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Baseline, Inpatient Days 1 to 4, Outpatient Days 5 to 7, Outpatient Weeks 2 through 8 and Outpatient Week >8 (or early termination) | CGI-I: 7-point clinician rated scale ranging from 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, to 7=very much worse. Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Scores above 4 reflect worsening of illness state as compared to baseline. |
| Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Baseline, Inpatient Days 1 to 4, Outpatient Days 5 to 7, Outpatient Weeks 2 through 8 and Outpatient Week >8 (or early termination) | CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1=normal, not ill at all, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill patients. Higher scores reflect higher severity of current illness states. |
| Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Baseline, Inpatient Days 1 to 4, Outpatient Days 5 to 7, Outpatient Weeks 2 through 8 and Outpatient Week >8 (or early termination) | HAM-D, clinician-rated interview, measures presence of depressive symptoms in 17 areas (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, & weight loss). Total score ranges from 0 to 52; higher scores reflect higher severity of current illness states. |
Countries
United States
Participant flow
Recruitment details
Treatment to be given at only 1 dose level at a time for at least the first 6 subjects per dose group. Approximately 6 to 8 subjects were to be enrolled in each of the dose cohorts; 4 dose levels were to be evaluated per age stratum in sequential manner and ascending order (10 to 100 milligrams (mg) for children; 25 to 200 mg for adolescents).
Pre-assignment details
Screening period 6 to 14 days followed by treatment period (up to 3.5 day inpatient and up to 7.5 week outpatient phase). Participants who enter outpatient period but do not continue into 6-month open-label extension study (NCT00669110) will participate in taper period of 0 to 2 weeks depending on dose of study treatment to which they are assigned.
Participants by arm
| Arm | Count |
|---|---|
| Desvenlafaxine 10 mg Children Desvenlafaxine sustained release 10 milligram (mg) tablet | 6 |
| Desvenlafaxine 25 mg Children Desvenlafaxine sustained release 25 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 56, 10 mg tablet for 7 day taper. | 7 |
| Desvenlafaxine 50 mg Children Desvenlafaxine sustained release 50 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 14, 50 mg tablet on days 15 through 56, 25 mg tablet on taper Days 1 through 7, 10 mg tablet for taper Days 8 through 14. | 9 |
| Desvenlafaxine 100 mg Children Desvenlafaxine sustained release 100 mg tablet on Day 1, 25 mg tablet on Days 4 through 7, 50 mg tablet on Days 8 through 14, 100 mg tablet on days 15 through 56, 50 mg tablet on taper Days 1 through 7, 25 mg tablet for taper Days 8 through 14. | 7 |
| Desvenlafaxine 25 mg Adolescent Desvenlafaxine sustained release 25 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 56, 10 mg tablet for 7 day taper. | 7 |
| Desvenlafaxine 50 mg Adolescent Desvenlafaxine sustained release 50 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 14, 50 mg tablet on days 15 through 56, 25 mg tablet on taper Days 1 through 7, 10 mg tablet for taper Days 8 through 14. | 7 |
| Desvenlafaxine 100 mg Adolescent Desvenlafaxine sustained release 100 mg tablet on Day 1, 25 mg tablet on Days 4 through 7, 50 mg tablet on Days 8 through 14, 100 mg tablet on days 15 through 56, 50 mg tablet on taper Days 1 through 7, 25 mg tablet for taper Days 8 through 14. | 8 |
| Desvenlafaxine 200 mg Adolescent Desvenlafaxine sustained release two 100 mg tablets on Day 1, 50 mg tablet on Days 4 through 7, 100 mg tablet on Days 8 through 14, two 100 mg tablets on days 15 through 56, 100 mg tablet on taper Days 1 through 7, 50 mg tablet for taper Days 8 through 14. | 8 |
| Total | 59 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| Overall Study | Physician Decision | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Protocol Violation | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
Baseline characteristics
| Characteristic | Desvenlafaxine 10 mg Children | Desvenlafaxine 25 mg Children | Desvenlafaxine 50 mg Children | Desvenlafaxine 100 mg Children | Desvenlafaxine 25 mg Adolescent | Desvenlafaxine 50 mg Adolescent | Desvenlafaxine 100 mg Adolescent | Desvenlafaxine 200 mg Adolescent | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | 8.83 years STANDARD_DEVIATION 1.33 | 9.57 years STANDARD_DEVIATION 1.13 | 9.89 years STANDARD_DEVIATION 1.27 | 9.71 years STANDARD_DEVIATION 0.95 | 15.00 years STANDARD_DEVIATION 1.83 | 13.14 years STANDARD_DEVIATION 1.46 | 14.25 years STANDARD_DEVIATION 1.67 | 14.00 years STANDARD_DEVIATION 1.6 | 11.86 years STANDARD_DEVIATION 2.71 |
| Children's Depression Ratings Scale-Revised (CDRS-R) total score | 57.50 scores on a scale STANDARD_DEVIATION 4.89 | 52.43 scores on a scale STANDARD_DEVIATION 5.13 | 49.89 scores on a scale STANDARD_DEVIATION 7.3 | 46.43 scores on a scale STANDARD_DEVIATION 4.35 | 64.86 scores on a scale STANDARD_DEVIATION 11.87 | 57.71 scores on a scale STANDARD_DEVIATION 1.98 | 57.88 scores on a scale STANDARD_DEVIATION 9.19 | 48.63 scores on a scale STANDARD_DEVIATION 6.25 | 54.17 scores on a scale STANDARD_DEVIATION 8.78 |
| Sex: Female, Male Female | 4 Participants | 3 Participants | 3 Participants | 4 Participants | 4 Participants | 3 Participants | 3 Participants | 5 Participants | 29 Participants |
| Sex: Female, Male Male | 2 Participants | 4 Participants | 6 Participants | 3 Participants | 3 Participants | 4 Participants | 5 Participants | 3 Participants | 30 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 1 / 6 | 3 / 7 | 3 / 9 | 7 / 7 | 4 / 7 | 2 / 7 | 7 / 8 | 8 / 8 |
| serious Total, serious adverse events | 0 / 6 | 0 / 7 | 0 / 9 | 0 / 7 | 1 / 7 | 0 / 7 | 0 / 8 | 0 / 8 |
Outcome results
Primary
Area Under the Curve From Time Zero to Infinity (AUC0-∞)
AUC (0-∞) = Area under the plasma concentration versus time curve from time zero (pre-dose) to infinity. Noncompartmental PK parameter obtained using 0 to 72 hour concentration data from venous blood samples measured as nanograms multiplied by hours divided by milliliters (ng\*hr/mL).
Time frame: Pre-dose (0 hour) and Post-dose (0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours) on Days 28 and 56
Population: PK population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Desvenlafaxine 10 mg Children | Area Under the Curve From Time Zero to Infinity (AUC0-∞) | 628 ng*hr/mL | Standard Deviation 346 |
| Desvenlafaxine 25 mg Children | Area Under the Curve From Time Zero to Infinity (AUC0-∞) | 1704 ng*hr/mL | Standard Deviation 553 |
| Desvenlafaxine 50 mg Children | Area Under the Curve From Time Zero to Infinity (AUC0-∞) | 2414 ng*hr/mL | Standard Deviation 924 |
| Desvenlafaxine 100 mg Children | Area Under the Curve From Time Zero to Infinity (AUC0-∞) | 6732 ng*hr/mL | Standard Deviation 3031 |
| Desvenlafaxine 25 mg Adolescent | Area Under the Curve From Time Zero to Infinity (AUC0-∞) | 1123 ng*hr/mL | Standard Deviation 361 |
| Desvenlafaxine 50 mg Adolescent | Area Under the Curve From Time Zero to Infinity (AUC0-∞) | 2281 ng*hr/mL | Standard Deviation 689 |
| Desvenlafaxine 100 mg Adolescent | Area Under the Curve From Time Zero to Infinity (AUC0-∞) | 5290 ng*hr/mL | Standard Deviation 2188 |
| Desvenlafaxine 200 mg Adolescent | Area Under the Curve From Time Zero to Infinity (AUC0-∞) | 11730 ng*hr/mL | Standard Deviation 3113 |
Primary
Maximum Observed Plasma Concentration (Cmax)
Noncompartmental pharmacokinetic (PK) parameter obtained using 0 to 72 hour concentration data from venous blood samples measured as nanograms per milliliter (ng/mL).
Time frame: Pre-dose (0 hour) and Post-dose (0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours) on Days 28 and 56
Population: PK population: all participants in the Safety population with available plasma concentration data from both the inpatient and outpatient phases of the study that are properly identified with respect to dosing and sampling times.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Desvenlafaxine 10 mg Children | Maximum Observed Plasma Concentration (Cmax) | 33.9 ng/mL | Standard Deviation 12.1 |
| Desvenlafaxine 25 mg Children | Maximum Observed Plasma Concentration (Cmax) | 98 ng/mL | Standard Deviation 60.5 |
| Desvenlafaxine 50 mg Children | Maximum Observed Plasma Concentration (Cmax) | 108 ng/mL | Standard Deviation 27 |
| Desvenlafaxine 100 mg Children | Maximum Observed Plasma Concentration (Cmax) | 263 ng/mL | Standard Deviation 66 |
| Desvenlafaxine 25 mg Adolescent | Maximum Observed Plasma Concentration (Cmax) | 46.1 ng/mL | Standard Deviation 15.9 |
| Desvenlafaxine 50 mg Adolescent | Maximum Observed Plasma Concentration (Cmax) | 93.9 ng/mL | Standard Deviation 15.5 |
| Desvenlafaxine 100 mg Adolescent | Maximum Observed Plasma Concentration (Cmax) | 202 ng/mL | Standard Deviation 92 |
| Desvenlafaxine 200 mg Adolescent | Maximum Observed Plasma Concentration (Cmax) | 449 ng/mL | Standard Deviation 126 |
Primary
Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs)
AEs are any untoward, undesired, or unplanned event in the form of signs, symptoms, disease, or laboratory or physiologic observations occurring in a person given study treatment. The event does not need to be causally related to the study treatment. SAEs are adverse events that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in persistent or significant disability or incapacity, result in cancer, or result in a congenital anomaly or birth defect.
Time frame: Baseline to Follow-up (up to Day 77)
Population: Safety population includes all treatment-assigned participants who have taken at least 1 dose of study treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Desvenlafaxine 10 mg Children | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Non-serious Adverse Events | 1 participants |
| Desvenlafaxine 10 mg Children | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Serious Adverse Events | 0 participants |
| Desvenlafaxine 25 mg Children | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Non-serious Adverse Events | 3 participants |
| Desvenlafaxine 25 mg Children | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Serious Adverse Events | 0 participants |
| Desvenlafaxine 50 mg Children | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Non-serious Adverse Events | 3 participants |
| Desvenlafaxine 50 mg Children | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Serious Adverse Events | 0 participants |
| Desvenlafaxine 100 mg Children | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Serious Adverse Events | 0 participants |
| Desvenlafaxine 100 mg Children | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Non-serious Adverse Events | 7 participants |
| Desvenlafaxine 25 mg Adolescent | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Serious Adverse Events | 1 participants |
| Desvenlafaxine 25 mg Adolescent | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Non-serious Adverse Events | 4 participants |
| Desvenlafaxine 50 mg Adolescent | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Non-serious Adverse Events | 2 participants |
| Desvenlafaxine 50 mg Adolescent | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Serious Adverse Events | 0 participants |
| Desvenlafaxine 100 mg Adolescent | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Serious Adverse Events | 0 participants |
| Desvenlafaxine 100 mg Adolescent | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Non-serious Adverse Events | 7 participants |
| Desvenlafaxine 200 mg Adolescent | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Non-serious Adverse Events | 8 participants |
| Desvenlafaxine 200 mg Adolescent | Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) | Serious Adverse Events | 0 participants |
Primary
Plasma Decay Half-Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Noncompartmental PK parameter obtained using 0 to 72 hour concentration data from venous blood samples measured as hours (hr).
Time frame: Pre-dose (0 hour) and Post-dose (0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours) on Days 28 and 56
Population: PK population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Desvenlafaxine 10 mg Children | Plasma Decay Half-Life (t1/2) | 7.8 hr | Standard Deviation 1.4 |
| Desvenlafaxine 25 mg Children | Plasma Decay Half-Life (t1/2) | 8.6 hr | Standard Deviation 1.6 |
| Desvenlafaxine 50 mg Children | Plasma Decay Half-Life (t1/2) | 9.4 hr | Standard Deviation 2.7 |
| Desvenlafaxine 100 mg Children | Plasma Decay Half-Life (t1/2) | 9.0 hr | Standard Deviation 2 |
| Desvenlafaxine 25 mg Adolescent | Plasma Decay Half-Life (t1/2) | 12 hr | Standard Deviation 3 |
| Desvenlafaxine 50 mg Adolescent | Plasma Decay Half-Life (t1/2) | 10.2 hr | Standard Deviation 3.7 |
| Desvenlafaxine 100 mg Adolescent | Plasma Decay Half-Life (t1/2) | 9.6 hr | Standard Deviation 2 |
| Desvenlafaxine 200 mg Adolescent | Plasma Decay Half-Life (t1/2) | 9.8 hr | Standard Deviation 2.7 |
Primary
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Noncompartmental PK parameter obtained using 0 to 72 hour concentration data from venous blood samples measured as hours (hr).
Time frame: Pre-dose (0 hour) and Post-dose (0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours) on Days 28 and 56
Population: PK population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Desvenlafaxine 10 mg Children | Time to Reach Maximum Observed Plasma Concentration (Tmax) | 4.7 hr | Standard Deviation 2.1 |
| Desvenlafaxine 25 mg Children | Time to Reach Maximum Observed Plasma Concentration (Tmax) | 4.3 hr | Standard Deviation 1.4 |
| Desvenlafaxine 50 mg Children | Time to Reach Maximum Observed Plasma Concentration (Tmax) | 5.1 hr | Standard Deviation 3 |
| Desvenlafaxine 100 mg Children | Time to Reach Maximum Observed Plasma Concentration (Tmax) | 5.0 hr | Standard Deviation 2 |
| Desvenlafaxine 25 mg Adolescent | Time to Reach Maximum Observed Plasma Concentration (Tmax) | 4.3 hr | Standard Deviation 0.7 |
| Desvenlafaxine 50 mg Adolescent | Time to Reach Maximum Observed Plasma Concentration (Tmax) | 8.7 hr | Standard Deviation 7.1 |
| Desvenlafaxine 100 mg Adolescent | Time to Reach Maximum Observed Plasma Concentration (Tmax) | 7.6 hr | Standard Deviation 3.4 |
| Desvenlafaxine 200 mg Adolescent | Time to Reach Maximum Observed Plasma Concentration (Tmax) | 7.5 hr | Standard Deviation 4.1 |
Secondary
Population Pharmacokinetics Dose Normalized AUC (AUC/D): First Method, Second Method
Relationship of variables (i.e., age, sex, ethnicity, and food) examined by fitting dose normalized AUC (AUC/D) values to a power model. AUC/D regressed against variables using power equation Y=A\*W\^b (Y=AUC/D; A=coefficient; W=variable; b=exponent). AUC values from children cohort (ages 7 to 11) combined doses=first method of analysis. AUC from adolescent cohort (ages 12 to 17) combined doses=second method of analysis. AUC values combined from both cohorts=third method of analysis. Measured as nanograms multiplied by hours divided by milliliters per milligram of dose \[(ng\*hr/mL)/mg of dose\].
Time frame: Day 1, Day 28, and Day 56
Population: PK population; data was insufficient examine the effect of age, sex, ethnicity, and food on the PK of desvenlafaxine. Coefficient and exponent values were calculated for variable of body weight, however, the AUC/D values were not summarized as descriptive statistics.
Secondary
Population Pharmacokinetics Dose Normalized AUC (AUC/D): Third Method
Relationship of variables (i.e., age, sex, ethnicity, and food) examined by fitting dose normalized AUC (AUC/D) values to a power model. AUC/D regressed against variables using power equation Y=A\*W\^b (Y=AUC/D; A=coefficient; W=variable; b=exponent). AUC values from children cohort (ages 7 to 11) combined doses=first method of analysis. AUC from adolescent cohort (ages 12 to 17) combined doses=second method of analysis. AUC values combined from both cohorts=third method of analysis. Measured as nanograms multiplied by hours divided by milliliters per milligram of dose \[(ng\*hr/mL)/mg of dose\].
Time frame: Day 1, Day 28, and Day 56
Population: PK population; data was insufficient examine the effect of age, sex, ethnicity, and food on the PK of desvenlafaxine. Coefficient and exponent values were calculated for variable of body weight, however, the AUC/D values were not summarized as descriptive statistics.
Other Pre-specified
Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score
CDRS-R total score: scale measures 17 depressive symptoms, of which 3 are rated 1 to 5 and 14 are rated 1 to 7 (1 = no symptom difficulties; 5 or 7 = severe clinically significant difficulties) for a total score range of 17 to 113. Lower total scores indicate lower intensity of symptoms.
Time frame: Baseline, Inpatient Days 1 to 4, Outpatient Days 5 to 7, Outpatient Weeks 2 through 8 and Outpatient Week >8 (or early termination)
Population: ITT: all treatment-assigned subjects with a baseline primary efficacy evaluation, at least 1 dose of study treatment, and at least 1 primary efficacy evaluation after the first dose of study treatment.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Desvenlafaxine 10 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 7 | -21.83 scores on a scale | Standard Deviation 6.77 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Days 5 to 7 | -10.67 scores on a scale | Standard Deviation 6.44 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 6 | -21.83 scores on a scale | Standard Deviation 6.77 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 8 | -22.00 scores on a scale | Standard Deviation 7.01 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 4 | -19.50 scores on a scale | Standard Deviation 6.5 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Inpatient Days 1 to 4 | -6.83 scores on a scale | Standard Deviation 6.15 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 5 | -19.50 scores on a scale | Standard Deviation 6.5 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 3 | -19.67 scores on a scale | Standard Deviation 6.77 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 2 | -17.67 scores on a scale | Standard Deviation 6.92 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week >8 | -22.00 scores on a scale | Standard Deviation 7.01 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Days 5 to 7 | -13.86 scores on a scale | Standard Deviation 8.51 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 6 | -19.86 scores on a scale | Standard Deviation 9.94 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 7 | -20.43 scores on a scale | Standard Deviation 10.06 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week >8 | -20.00 scores on a scale | Standard Deviation 7.05 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 2 | -18.86 scores on a scale | Standard Deviation 10.51 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 3 | -18.57 scores on a scale | Standard Deviation 7.93 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 8 | -20.29 scores on a scale | Standard Deviation 7.18 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 4 | -20.86 scores on a scale | Standard Deviation 10.98 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Inpatient Days 1 to 4 | -9.86 scores on a scale | Standard Deviation 5.4 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 5 | -23.00 scores on a scale | Standard Deviation 8.56 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 5 | -19.56 scores on a scale | Standard Deviation 13.46 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 2 | -14.44 scores on a scale | Standard Deviation 12.68 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 3 | -16.89 scores on a scale | Standard Deviation 13.49 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 8 | -19.78 scores on a scale | Standard Deviation 14.49 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Inpatient Days 1 to 4 | -2.78 scores on a scale | Standard Deviation 3.07 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 4 | -17.56 scores on a scale | Standard Deviation 15.99 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 6 | -18.44 scores on a scale | Standard Deviation 13.79 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Days 5 to 7 | -10.44 scores on a scale | Standard Deviation 10.79 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week >8 | -19.89 scores on a scale | Standard Deviation 14.51 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 7 | -19.11 scores on a scale | Standard Deviation 13.2 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 3 | -10.43 scores on a scale | Standard Deviation 9.11 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Inpatient Days 1 to 4 | -6.43 scores on a scale | Standard Deviation 10 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Days 5 to 7 | -7.86 scores on a scale | Standard Deviation 8.28 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 4 | -10.00 scores on a scale | Standard Deviation 4.69 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 7 | -12.00 scores on a scale | Standard Deviation 5.48 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 6 | -12.00 scores on a scale | Standard Deviation 5.48 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 2 | -9.57 scores on a scale | Standard Deviation 10.83 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 8 | -14.14 scores on a scale | Standard Deviation 6.52 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 5 | -10.29 scores on a scale | Standard Deviation 4.39 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week >8 | -14.14 scores on a scale | Standard Deviation 6.52 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 3 | -11.71 scores on a scale | Standard Deviation 13.23 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 7 | -20.57 scores on a scale | Standard Deviation 18.98 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week >8 | -21.43 scores on a scale | Standard Deviation 19.86 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 5 | -14.57 scores on a scale | Standard Deviation 14.06 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 6 | -20.57 scores on a scale | Standard Deviation 18.98 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Inpatient Days 1 to 4 | -7.00 scores on a scale | Standard Deviation 18.18 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Days 5 to 7 | -8.00 scores on a scale | Standard Deviation 13.88 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 2 | -8.29 scores on a scale | Standard Deviation 13.46 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 4 | -14.57 scores on a scale | Standard Deviation 14.06 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 8 | -21.43 scores on a scale | Standard Deviation 19.86 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 8 | -22.29 scores on a scale | Standard Deviation 3.09 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Inpatient Days 1 to 4 | -4.57 scores on a scale | Standard Deviation 2.99 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Days 5 to 7 | -8.29 scores on a scale | Standard Deviation 4.27 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 3 | -14.57 scores on a scale | Standard Deviation 6.19 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 4 | -19.43 scores on a scale | Standard Deviation 9.43 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 5 | -19.43 scores on a scale | Standard Deviation 9.43 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 6 | -17.14 scores on a scale | Standard Deviation 6.2 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 7 | -17.14 scores on a scale | Standard Deviation 6.2 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 2 | -11.29 scores on a scale | Standard Deviation 5.53 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week >8 | -22.29 scores on a scale | Standard Deviation 3.09 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 5 | -23.88 scores on a scale | Standard Deviation 10.36 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 7 | -25.38 scores on a scale | Standard Deviation 7.87 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 4 | -23.50 scores on a scale | Standard Deviation 10.69 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 3 | -21.25 scores on a scale | Standard Deviation 10.99 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 2 | -18.13 scores on a scale | Standard Deviation 11.12 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week >8 | -26.75 scores on a scale | Standard Deviation 7.42 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 8 | -27.25 scores on a scale | Standard Deviation 6.78 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Days 5 to 7 | -9.50 scores on a scale | Standard Deviation 8.11 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Inpatient Days 1 to 4 | -8.25 scores on a scale | Standard Deviation 4.33 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 6 | -24.63 scores on a scale | Standard Deviation 8.99 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 6 | -14.38 scores on a scale | Standard Deviation 9.93 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week >8 | -15.38 scores on a scale | Standard Deviation 8.65 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 8 | -15.38 scores on a scale | Standard Deviation 8.65 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 7 | -14.50 scores on a scale | Standard Deviation 9.89 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Days 5 to 7 | -11.25 scores on a scale | Standard Deviation 14 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 3 | -13.13 scores on a scale | Standard Deviation 11.47 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 4 | -12.50 scores on a scale | Standard Deviation 9.41 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 2 | -13.13 scores on a scale | Standard Deviation 14.88 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Inpatient Days 1 to 4 | -10.38 scores on a scale | Standard Deviation 13.45 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score | Outpatient Week 5 | -12.50 scores on a scale | Standard Deviation 9.41 |
Other Pre-specified
Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score
HAM-D, clinician-rated interview, measures presence of depressive symptoms in 17 areas (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, & weight loss). Total score ranges from 0 to 52; higher scores reflect higher severity of current illness states.
Time frame: Baseline, Inpatient Days 1 to 4, Outpatient Days 5 to 7, Outpatient Weeks 2 through 8 and Outpatient Week >8 (or early termination)
Population: ITT
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Desvenlafaxine 10 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Days 5 to 7 | -6.00 Score on a scale | Standard Deviation 5.73 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Inpatient Days 1 to 4 | -6.00 Score on a scale | Standard Deviation 5.73 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 2 | -9.33 Score on a scale | Standard Deviation 7 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week >8 | -12.17 Score on a scale | Standard Deviation 6.01 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 3 | -9.33 Score on a scale | Standard Deviation 7 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 8 | -12.17 Score on a scale | Standard Deviation 6.01 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 4 | -11.00 Score on a scale | Standard Deviation 5.62 |
| Desvenlafaxine 10 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 5 | -11.00 Score on a scale | Standard Deviation 5.62 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 4 | -13.00 Score on a scale | Standard Deviation 6.3 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Days 5 to 7 | -5.43 Score on a scale | Standard Deviation 4.31 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Inpatient Days 1 to 4 | -5.43 Score on a scale | Standard Deviation 4.31 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 3 | -10.29 Score on a scale | Standard Deviation 5.41 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 2 | -10.71 Score on a scale | Standard Deviation 4.61 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week >8 | -13.86 Score on a scale | Standard Deviation 4.81 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 8 | -14.00 Score on a scale | Standard Deviation 4.62 |
| Desvenlafaxine 25 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 5 | -14.14 Score on a scale | Standard Deviation 4.1 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 4 | -7.22 Score on a scale | Standard Deviation 5.61 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 3 | -6.11 Score on a scale | Standard Deviation 2.67 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 5 | -7.56 Score on a scale | Standard Deviation 5.64 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 8 | -8.44 Score on a scale | Standard Deviation 6.88 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week >8 | -9.11 Score on a scale | Standard Deviation 6.68 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Inpatient Days 1 to 4 | -0.33 Score on a scale | Standard Deviation 1.94 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Days 5 to 7 | -0.33 Score on a scale | Standard Deviation 1.94 |
| Desvenlafaxine 50 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 2 | -6.11 Score on a scale | Standard Deviation 2.67 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week >8 | -11.14 Score on a scale | Standard Deviation 4.14 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 4 | -7.57 Score on a scale | Standard Deviation 3.05 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 3 | -5.57 Score on a scale | Standard Deviation 4.2 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Days 5 to 7 | -2.43 Score on a scale | Standard Deviation 6.92 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 2 | -5.57 Score on a scale | Standard Deviation 4.2 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 8 | -11.14 Score on a scale | Standard Deviation 4.14 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 5 | -9.00 Score on a scale | Standard Deviation 1.91 |
| Desvenlafaxine 100 mg Children | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Inpatient Days 1 to 4 | -2.43 Score on a scale | Standard Deviation 6.92 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 5 | -7.29 Score on a scale | Standard Deviation 5.19 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week >8 | -11.14 Score on a scale | Standard Deviation 9.56 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 8 | -11.14 Score on a scale | Standard Deviation 9.56 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 3 | -2.71 Score on a scale | Standard Deviation 4.27 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 4 | -7.29 Score on a scale | Standard Deviation 5.19 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Days 5 to 7 | -2.00 Score on a scale | Standard Deviation 7.59 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Inpatient Days 1 to 4 | -2.29 Score on a scale | Standard Deviation 7.45 |
| Desvenlafaxine 25 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 2 | -2.71 Score on a scale | Standard Deviation 4.27 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Days 5 to 7 | -0.57 Score on a scale | Standard Deviation 1.13 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 8 | -9.86 Score on a scale | Standard Deviation 3.93 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 3 | -5.71 Score on a scale | Standard Deviation 3.4 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week >8 | -9.86 Score on a scale | Standard Deviation 3.93 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Inpatient Days 1 to 4 | -0.57 Score on a scale | Standard Deviation 1.13 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 2 | -5.71 Score on a scale | Standard Deviation 3.4 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 4 | -7.57 Score on a scale | Standard Deviation 2.99 |
| Desvenlafaxine 50 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 5 | -7.57 Score on a scale | Standard Deviation 2.99 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 3 | -8.13 Score on a scale | Standard Deviation 4.91 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Inpatient Days 1 to 4 | -1.50 Score on a scale | Standard Deviation 4.54 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 8 | -14.25 Score on a scale | Standard Deviation 3.96 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 5 | -12.25 Score on a scale | Standard Deviation 5.73 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 2 | -8.13 Score on a scale | Standard Deviation 4.91 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week >8 | -13.00 Score on a scale | Standard Deviation 5.37 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 4 | -12.13 Score on a scale | Standard Deviation 5.69 |
| Desvenlafaxine 100 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Days 5 to 7 | -1.50 Score on a scale | Standard Deviation 4.54 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Days 5 to 7 | -5.63 Score on a scale | Standard Deviation 7.42 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Inpatient Days 1 to 4 | -5.63 Score on a scale | Standard Deviation 7.42 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 4 | -9.00 Score on a scale | Standard Deviation 5.24 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 3 | -8.88 Score on a scale | Standard Deviation 6.33 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 5 | -9.00 Score on a scale | Standard Deviation 5.24 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week >8 | -11.63 Score on a scale | Standard Deviation 5.4 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 2 | -9.38 Score on a scale | Standard Deviation 7.41 |
| Desvenlafaxine 200 mg Adolescent | Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score | Outpatient Week 8 | -11.63 Score on a scale | Standard Deviation 5.4 |
Other Pre-specified
Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit
CGI-I: 7-point clinician rated scale ranging from 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, to 7=very much worse. Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Scores above 4 reflect worsening of illness state as compared to baseline.
Time frame: Baseline, Inpatient Days 1 to 4, Outpatient Days 5 to 7, Outpatient Weeks 2 through 8 and Outpatient Week >8 (or early termination)
Population: ITT; no participants had a CGI-I score of 6 or 7, therefore only scores 1 through 5 are reported.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: no change | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally improved | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally improved | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: no change | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: no change | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: much improved | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: much improved | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally improved | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: much improved | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: much improved | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: no change | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: much improved | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: much improved | 33.3 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally improved | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: no change | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: much improved | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally improved | 16.7 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally improved | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally improved | 16.7 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally improved | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: much improved | 83.3 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: no change | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: no change | 16.7 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally improved | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: much improved | 83.3 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally improved | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: much improved | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: no change | 100 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: no change | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: no change | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: no change | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally improved | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: much improved | 71.4 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: very much improved | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: much improved | 85.7 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: no change | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: no change | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally improved | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally improved | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: very much improved | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally improved | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: much improved | 71.4 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: much improved | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: no change | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally improved | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally improved | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: much improved | 71.4 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: very much improved | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: no change | 71.4 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: no change | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: much improved | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: very much improved | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: no change | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally improved | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: much improved | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: much improved | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: very much improved | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally improved | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: no change | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: no change | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: no change | 100 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: much improved | 85.7 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: very much improved | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: very much improved | 22.2 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally improved | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: much improved | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally improved | 55.6 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: no change | 33.3 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: very much improved | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: much improved | 44.4 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally improved | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: no change | 33.3 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: much improved | 44.4 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally improved | 44.4 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: no change | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally improved | 22.2 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: no change | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally worse | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: very much improved | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: much improved | 55.6 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally improved | 22.2 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: no change | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally worse | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: very much improved | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: much improved | 66.7 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally improved | 22.2 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: no change | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: much improved | 55.6 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: no change | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: very much improved | 22.2 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: much improved | 22.2 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally improved | 55.6 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: no change | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: much improved | 33.3 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: much improved | 55.6 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: very much improved | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally improved | 33.3 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally improved | 44.4 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: no change | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: no change | 88.9 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: much improved | 28.6 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: no change | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: much improved | 71.4 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: much improved | 28.6 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: much improved | 28.6 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally improved | 71.4 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: no change | 42.9 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally improved | 71.4 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: no change | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: no change | 14.3 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: much improved | 14.3 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally improved | 42.9 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally improved | 57.1 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: no change | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: much improved | 28.6 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: much improved | 14.3 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally improved | 71.4 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: no change | 85.7 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: no change | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: no change | 28.6 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: no change | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally improved | 57.1 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: no change | 57.1 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: much improved | 14.3 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally improved | 28.6 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally improved | 42.9 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: much improved | 71.4 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally improved | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: much improved | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: no change | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally improved | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: no change | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally improved | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: no change | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: no change | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: much improved | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: much improved | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally improved | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally improved | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: much improved | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: no change | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: no change | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: no change | 85.7 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: no change | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: no change | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: much improved | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally improved | 0.00 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally improved | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: much improved | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally improved | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: much improved | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: much improved | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally improved | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally improved | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: no change | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally improved | 57.1 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: no change | 14.3 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally improved | 57.1 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: no change | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally improved | 28.6 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally improved | 85.7 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: no change | 14.3 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: no change | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally improved | 28.6 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: no change | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally improved | 71.4 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: much improved | 71.4 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: much improved | 71.4 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: no change | 100 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally improved | 85.7 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: no change | 42.9 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally improved | 28.6 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally improved | 57.1 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: no change | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: no change | 42.9 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: no change | 28.6 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: much improved | 71.4 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: much improved | 71.4 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: much improved | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally improved | 28.6 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: much improved | 50 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally improved | 37.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: no change | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: no change | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: no change | 25 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: much improved | 50 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally improved | 37.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally improved | 75 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: no change | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: much improved | 75 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally improved | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: no change | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: no change | 75 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: no change | 87.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: no change | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally improved | 25 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: very much improved | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: much improved | 75 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: no change | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: much improved | 75 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: much improved | 75 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally improved | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally improved | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: very much improved | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally improved | 37.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: much improved | 37.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: no change | 25 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: no change | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally improved | 37.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: much improved | 37.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: much improved | 12.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: much improved | 62.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: no change | 50 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: no change | 25 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally improved | 37.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: much improved | 12.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: much improved | 37.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: no change | 12.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: minimally improved | 37.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: no change | 62.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally improved | 62.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: much improved | 25 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally worse | 12.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: no change | 25 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: no change | 12.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: no change | 12.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: minimally improved | 25 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: much improved | 50 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 6: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: much improved | 25 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally worse | 12.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 4: minimally improved | 37.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 3: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: no change | 12.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 7: much improved | 50 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 5: minimally improved | 37.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: minimally improved | 25 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: no change | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week >8: much improved | 62.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 8: minimally worse | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Days 5 to 7: very much improved | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Inpatient Days 1 to 4: minimally improved | 37.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit | Outpatient Week 2: minimally improved | 50 percentage of participants |
Other Pre-specified
Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1=normal, not ill at all, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill patients. Higher scores reflect higher severity of current illness states.
Time frame: Baseline, Inpatient Days 1 to 4, Outpatient Days 5 to 7, Outpatient Weeks 2 through 8 and Outpatient Week >8 (or early termination)
Population: ITT; no participants had a CGI-S score of 6 or 7, therefore only scores 1 through 5 are reported.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: mildly ill | 66.7 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: moderately ill | 16.7 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: borderline ill | 16.7 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: mildly ill | 66.7 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: mildly ill | 66.7 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: borderline ill | 66.7 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: mildly ill | 33.3 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: mildly ill | 66.7 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: moderately ill | 100 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: moderately ill | 33.3 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: borderline ill | 16.7 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: mildly ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: moderately ill | 16.7 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: borderline ill | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: borderline ill | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: mildly ill | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: moderately ill | 100 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: moderately ill | 33.3 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: mildly ill | 50 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: mildly ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: borderline ill | 66.7 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: mildly ill | 33.3 percentage of participants |
| Desvenlafaxine 10 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: not ill at all | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: borderline ill | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: borderline ill | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: mildly ill | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: borderline ill | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: moderately ill | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: borderline ill | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: borderline ill | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: mildly ill | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: mildly ill | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: mildly ill | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: borderline ill | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: borderline ill | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: mildly ill | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: mildly ill | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: moderately ill | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: borderline ill | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: mildly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: mildly ill | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: not ill at all | 14.3 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: mildly ill | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: moderately ill | 100 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: mildly ill | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: mildly ill | 66.7 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: mildly ill | 55.6 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: mildly ill | 88.9 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: moderately ill | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: not ill at all | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: borderline ill | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: borderline ill | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: mildly ill | 77.8 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: not ill at all | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: not ill at all | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: borderline ill | 22.2 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: not ill at all | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: moderately ill | 22.2 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: mildly ill | 55.6 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: borderline ill | 33.3 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: borderline ill | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: not ill at all | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: mildly ill | 66.7 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: mildly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: moderately ill | 88.9 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: markedly ill | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: moderately ill | 22.2 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: mildly ill | 44.4 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: moderately ill | 33.3 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: mildly ill | 66.7 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: moderately ill | 55.6 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: moderately ill | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: borderline ill | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: borderline ill | 11.1 percentage of participants |
| Desvenlafaxine 50 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: mildly ill | 55.6 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: moderately ill | 28.6 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: mildly ill | 71.4 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: moderately ill | 85.7 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: mildly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: mildly ill | 14.3 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: moderately ill | 85.7 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: moderately ill | 71.4 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: moderately ill | 71.4 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: mildly ill | 28.6 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: mildly ill | 28.6 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: moderately ill | 85.7 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: moderately ill | 100 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: mildly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: mildly ill | 14.3 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: moderately ill | 100 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: mildly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: mildly ill | 14.3 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: moderately ill | 100 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: moderately ill | 28.6 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Children | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: mildly ill | 71.4 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: moderately ill | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: mildly ill | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: mildly ill | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: mildly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: moderately ill | 71.4 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: mildly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: moderately ill | 71.4 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: mildly ill | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: moderately ill | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: moderately ill | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: moderately ill | 100 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: moderately ill | 100 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: mildly ill | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: mildly ill | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: mildly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: mildly ill | 28.6 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: moderately ill | 71.4 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: moderately ill | 100 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: moderately ill | 42.9 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: mildly ill | 57.1 percentage of participants |
| Desvenlafaxine 25 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: mildly ill | 28.6 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: mildly ill | 85.7 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: borderline ill | 14.3 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: mildly ill | 57.1 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: moderately ill | 28.6 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: borderline ill | 14.3 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: mildly ill | 57.1 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: moderately ill | 28.6 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: borderline ill | 28.6 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: mildly ill | 71.4 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: borderline ill | 28.6 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: mildly ill | 71.4 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: moderately ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: mildly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: moderately ill | 100 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: mildly ill | 14.3 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: moderately ill | 85.7 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: moderately ill | 71.4 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: mildly ill | 57.1 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: moderately ill | 42.9 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: moderately ill | 14.3 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: mildly ill | 85.7 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: moderately ill | 14.3 percentage of participants |
| Desvenlafaxine 50 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: moderately ill | 50 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: borderline ill | 62.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: borderline ill | 50 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: moderately ill | 100 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: mildly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: mildly ill | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: moderately ill | 37.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: moderately ill | 100 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: mildly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: borderline ill | 50 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: moderately ill | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: mildly ill | 25 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: borderline ill | 50 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: borderline ill | 25 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: not ill at all | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: mildly ill | 50 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: mildly ill | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: moderately ill | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: mildly ill | 25 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: borderline ill | 50 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: moderately ill | 37.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: not ill at all | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: mildly ill | 25 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: borderline ill | 62.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: mildly ill | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: moderately ill | 12.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: moderately ill | 25 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: moderately ill | 37.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: mildly ill | 37.5 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 100 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: moderately ill | 87.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: moderately ill | 87.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: mildly ill | 12.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: mildly ill | 50 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: moderately ill | 87.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: moderately ill | 37.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: mildly ill | 12.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: mildly ill | 37.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: mildly ill | 37.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Days 5 to 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: moderately ill | 50 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: mildly ill | 62.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: moderately ill | 62.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: mildly ill | 12.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: moderately ill | 87.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 8: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: mildly ill | 12.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: mildly ill | 50 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 2: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: moderately ill | 62.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 4: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Inpatient Days 1 to 4: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: moderately ill | 37.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 3: borderline ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 6: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 5: not ill at all | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week 7: moderately ill | 50 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: mildly ill | 62.5 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: markedly ill | 0.0 percentage of participants |
| Desvenlafaxine 200 mg Adolescent | Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit | Outpatient Week >8: borderline ill | 0.0 percentage of participants |